Suzanne Fleming
Comptroller/Controller/Auditor chez BEAM THERAPEUTICS INC.
Profil
Suzanne Fleming is currently the Chief Accounting Officer at Beam Therapeutics, Inc. She previously held positions as the Senior Director-Finance at TransForm Pharmaceuticals, Inc. from 2003 to 2005, Principal at Transkaryotic Therapies, Inc., Principal at Oculon Corp from 1991 to 1995, Principal at CytoTherapuetics, Inc. from 1995 to 1998, Vice President-Finance at AVEO Pharmaceuticals, Inc. from 2005 to 2013, Treasurer, Chief Financial & Accounting Officer at Epizyme, Inc. from 2017 to 2019, and Vice President-Finance at Foundation Medicine, Inc. from 2014 to 2017.
She obtained her undergraduate degree from Stonehill College, Inc.
Postes actifs de Suzanne Fleming
| Sociétés | Poste | Début |
|---|---|---|
| BEAM THERAPEUTICS INC. | Comptroller/Controller/Auditor | - |
Anciens postes connus de Suzanne Fleming
| Sociétés | Poste | Fin |
|---|---|---|
| EPIZYME, INC. | Directeur Financier/CFO | 31/01/2019 |
| FOUNDATION MEDICINE INC | Corporate Officer/Principal | 01/09/2017 |
| AVEO PHARMACEUTICALS, INC. | Directeur Financier/CFO | 05/04/2011 |
TransForm Pharmaceuticals, Inc.
 TransForm Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology TransForm Pharmaceuticals, Inc. develops and manufactures drugs. It integrates pharmaceutical sciences, materials science and high throughput experimentation by enabling novel technology. The company was founded by Nicholas Galakatos in 1999 and is headquartered in Lexington, MA. | Directeur Financier/CFO | 01/01/2005 |
| CytoTherapuetics, Inc. | Corporate Officer/Principal | 01/01/1998 |
Formation de Suzanne Fleming
| Stonehill College, Inc. | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BEAM THERAPEUTICS INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Transkaryotic Therapies, Inc.
 Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | Commercial Services |
Oculon Corp
 Oculon Corp Pharmaceuticals: MajorHealth Technology Part of W World Corp., Oculon Corp is a pharmaceutical concern. Oculon was acquired by W World Corp. on April 13, 1995 for $4 million. | Health Technology |
| CytoTherapuetics, Inc. | Finance |
TransForm Pharmaceuticals, Inc.
TransForm Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology TransForm Pharmaceuticals, Inc. develops and manufactures drugs. It integrates pharmaceutical sciences, materials science and high throughput experimentation by enabling novel technology. The company was founded by Nicholas Galakatos in 1999 and is headquartered in Lexington, MA. | Health Technology |
AVEO Pharmaceuticals, Inc.
 AVEO Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA. | Health Technology |
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
Foundation Medicine, Inc.
 Foundation Medicine, Inc. Medical/Nursing ServicesHealth Services Foundation Medicine, Inc. is a molecular information company, which engages in the provision of information on clinical treatment decisions for patients with cancer. The company was founded on January 10, 2010 and is headquartered in Cambridge, MA. | Health Services |
